December 29, 2025 — Harbour BioMed announced a long-term strategic collaboration with Yantai Lannacheng Biotechnology Co., Ltd. (Lannacheng). Leveraging their respective resources and strengths, the two parties will jointly advance the development of next-generation Radionuclide Drug Conjugates (RDCs).
Compared with conventional radiotherapy, Radionuclide Drug Conjugates (RDCs) utilize tumor antigen-specific molecular ligands to precisely deliver radionuclides directly into tumor lesions for radiotherapy, thereby effectively minimizing damage to surrounding normal tissues.
In contrast to Antibody-Drug Conjugates (ADCs), the radionuclides in RDCs can also exert cytotoxic effects on tumor cells adjacent to target cells and their microenvironment, even if these cells do not express the target antigen themselves. This confers a potential mechanistic advantage in overcoming tumor heterogeneity and drug resistance. Additionally, this technology holds promise for enabling theranostics (the integration of diagnosis and therapy).
Harbour BioMed's proprietary Harbour Mice® technology platform is capable of generating fully human monoclonal antibodies in both conventional H2L2 antibody and heavy chain-only antibody (HCAb) formats, eliminating the need for additional humanization steps or complex antibody engineering. Notably, HCAb antibodies are approximately half the size of traditional IgG antibodies, offering significant advantages for the development of next-generation antibody therapeutics. In RDC development, fully human antibodies' low immunogenicity, excellent tissue penetration capabilities, and high specificity and stability can significantly enhance targeted delivery efficiency, thereby improving therapeutic efficacy while effectively reducing drug toxicity and side effects.
Founded in 2021, Yantai Lannacheng Biotechnology Co., Ltd. (Lannacheng) is a clinical-stage biotech company dedicated to the discovery, development, and commercialization of theranostic radiopharmaceuticals for oncology. Lannacheng's research and development engine integrates target validation, radioisotope selection, and linker design, further enhanced by its proprietary pharmacokinetic modification technology and dual-target radiopharmaceutical development technology. These capabilities improve pharmacokinetic properties and advance the development of dual-target radiopharmaceutical candidates. Leveraging end-to-end integration of research and development support, stable radioisotope supply, and GMP production capacity under construction in Yantai from its controlling shareholder, Dongcheng Pharmaceutical Group, Lannacheng further strengthens its competitive edge, ensuring the continuity, scalability, and accelerated innovation of radiopharmaceuticals.